Hulk Hogan, wrestling icon, dies at 71 in Florida home
Kamada Ltd (NASDAQ:KMDA)., a pharmaceutical company specializing in plasma-derived protein therapeutics, has announced the opening of a new plasma collection facility in San Antonio, Texas. This move, disclosed in a report filed today with the Securities and Exchange Commission (SEC), represents an expansion of the company’s operations in the field of plasma collection.
The new facility in San Antonio is part of Kamada’s strategic initiative to enhance its plasma collection capabilities. Plasma, the liquid component of blood, contains proteins that are essential for various therapeutic treatments, including those developed and manufactured by Kamada. The collection of plasma is a critical step in the production of these life-saving treatments.
Kamada, headquartered in Rehovot, Israel, has been operating under the name 03 Life Sciences and is incorporated in L3. The company files annual reports with the SEC under Form 20-F and has several Form S-8 Registration Statements on file related to its equity compensation plans.
The announcement of the new plasma collection site was included as Exhibit 99.1 in the company’s Form 6-K filing, which serves as a report of foreign private issuers to the SEC. The filing also indicates that this Form 6-K is incorporated by reference into the Registrant’s Form S-8 Registration Statements, which pertain to employee equity compensation.
Kamada’s expansion into San Antonio aligns with its ongoing efforts to secure a stable and self-sufficient supply of plasma. This is crucial for the company’s ability to meet the demand for its plasma-based products and to maintain control over the quality and availability of the raw materials used in its product development.
The opening of the new collection site is a significant step for Kamada as it continues to grow its presence in the global healthcare market. The company’s focus on plasma-derived therapeutics positions it within a niche but vital segment of the pharmaceutical industry, addressing a range of conditions including immune deficiencies, coagulation disorders, and critical care. InvestingPro analysis indicates that Kamada is currently undervalued, with analysts setting price targets between $11 and $20. For deeper insights into Kamada’s valuation and growth potential, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, along with 6 additional ProTips and extensive financial metrics.
The information regarding Kamada’s expansion is based on the company’s recent SEC filing and reflects the company’s ongoing commitment to enhancing its plasma collection infrastructure.
In other recent news, Kamada Ltd reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of $0.07, which exceeded analysts’ expectations of $0.05. The company’s revenue for the quarter was $39.01 million, slightly below the forecasted $40.11 million. For the full year 2024, Kamada achieved a total revenue of $161 million, marking a 13% increase from the previous year, and net income rose to $14.5 million, or $0.25 per diluted share, representing a 75% increase from 2023. Kamada also declared a special cash dividend of $0.20 per share, signaling strong financial health.
H.C. Wainwright maintained a Buy rating on Kamada, with a price target of $11.00, citing the company’s strong performance and growth potential in its therapeutic pipeline. The analyst, Andrew S. Fein, noted Kamada’s unique position as both a plasma business and a biotechnology firm, offering stability and potential growth from its inhaled Alpha-1 Antitrypsin program. Fein also discussed Kamada’s strategic decision to issue a special dividend and its ongoing discussions about acquiring external commercial assets.
Looking ahead, Kamada forecasts significant growth in 2025, with a revenue target of $178-182 million and an adjusted EBITDA of $38-42 million. The company plans to launch two additional biosimilar products in 2025, aiming for annual sales of $15-20 million within five years. Kamada’s CEO, Amir London, emphasized the company’s focus on growth through organic expansion, clinical development, mergers and acquisitions, and plasma collection expansion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.